Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria.

Antibiotics for emerging pathogens. Science (2009) 7.39

Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother (2007) 3.44

Polymyxins revisited. Clin Microbiol Rev (2008) 3.16

Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis (2013) 2.01

Colistin administration to pediatric and neonatal patients. Eur J Pediatr (2010) 1.83

The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob Agents Chemother (2011) 1.78

Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy (2010) 1.59

Acinetobacter baumannii secretes cytotoxic outer membrane protein A via outer membrane vesicles. PLoS One (2011) 1.24

High-throughput platform for the discovery of elicitors of silent bacterial gene clusters. Proc Natl Acad Sci U S A (2014) 1.20

Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? Diagn Microbiol Infect Dis (2012) 1.20

Poly-N-acetyl-β-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections. Infect Immun (2011) 1.17

The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res (2006) 1.14

Efficient direct extended-spectrum β-lactamase detection by multiplex real-time PCR: accurate assignment of phenotype by use of a limited set of genetic markers. J Clin Microbiol (2011) 1.06

Productive steps toward an antimicrobial targeting virulence. Curr Opin Microbiol (2009) 1.02

Infections by pandrug-resistant gram-negative bacteria: clinical profile, therapeutic management, and outcome in a series of 21 patients. Eur J Clin Microbiol Infect Dis (2010) 0.96

Activity of Chitosans in combination with antibiotics in Pseudomonas aeruginosa. Int J Biol Sci (2009) 0.94

Rate of isolation and trends of antimicrobial resistance of multidrug resistant pseudomonas aeruginosa from otorrhea in chronic suppurative otitis media. Clin Exp Otorhinolaryngol (2012) 0.90

Rapid identification of international multidrug-resistant Pseudomonas aeruginosa clones by multiple-locus variable number of tandem repeats analysis and investigation of their susceptibility to lytic bacteriophages. Antimicrob Agents Chemother (2012) 0.87

Complicated skin, skin structure and soft tissue infections - are we threatened by multi-resistant pathogens? Eur J Med Res (2010) 0.86

Complexes of bacterial nicotinate mononucleotide adenylyltransferase with inhibitors: implication for structure-based drug design and improvement. J Med Chem (2010) 0.85

Chitosan-EDTA new combination is a promising candidate for treatment of bacterial and fungal infections. Curr Microbiol (2010) 0.83

Genomic characterization of JG068, a novel virulent podovirus active against Burkholderia cenocepacia. BMC Genomics (2013) 0.83

Multi-drug-resistant gram-negative bacterial infection in surgical patients hospitalized in the ICU: a cohort study. Eur J Clin Microbiol Infect Dis (2011) 0.82

Antibacterial Discovery and Development: From Gene to Product and Back. Biomed Res Int (2015) 0.81

The Effect of Colistin Resistance-Associated Mutations on the Fitness of Acinetobacter baumannii. Front Microbiol (2016) 0.78

Membrane permeabilization of colistin toward pan-drug resistant Gram-negative isolates. Braz J Microbiol (2016) 0.78

Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis. Indian J Pharmacol (2015) 0.76

Nitric oxide (NO)-induced death of gram-negative bacteria from a light-controlled NO-releasing platform. Chem Biodivers (2012) 0.75

Functional Site Discovery in a Sulfur Metabolism Enzyme by Using Directed Evolution. Chembiochem (2016) 0.75

Surveillance of Gram-negative bacteria: impact of variation in current European laboratory reporting practice on apparent multidrug resistance prevalence in paediatric bloodstream isolates. Eur J Clin Microbiol Infect Dis (2016) 0.75

Nanosilver-marine fungal chitosan as antibiotic synergizers against sepsis fish bacteria. Iran J Microbiol (2015) 0.75

In vivo efficacy of humanized high dose meropenem and comparators against Pseudomonas aeruginosa isolates producing verona integron-encoded metallo-β-lactamase (VIM). Heliyon (2016) 0.75

Carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii at Mulago Hospital in Kampala, Uganda (2007-2009). Springerplus (2016) 0.75

Molecular Epidemiology and Risk Factors of Carbapenem-Resistant Klebsiella pneumoniae Infections in Eastern China. Front Microbiol (2017) 0.75

Protective effects of ginsenoside Rg1 against colistin sulfate-induced neurotoxicity in PC12 cells. Cell Mol Neurobiol (2013) 0.75

Multi-hospital occurrence of pan-resistant Klebsiella pneumoniae ST147 with an ISEcp1-directed blaOXA-181 insertion into the mgrB gene in the United Arab Emirates. Antimicrob Agents Chemother (2017) 0.75

Genotypic diversity among multidrug resistant Pseudomonas aeruginosa and Acinetobacter species at Mulago Hospital in Kampala, Uganda. BMC Res Notes (2017) 0.75

Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis (2005) 6.60

PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol (1998) 5.01

Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin. J Bacteriol (1980) 4.93

Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol (2001) 3.49

Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect (2005) 3.39

Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis (2003) 3.37

Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis (2000) 2.50

A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother (1997) 2.37

Regulation of polymyxin resistance and adaptation to low-Mg2+ environments. J Bacteriol (1997) 2.29

Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis (2002) 2.29

Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrob Agents Chemother (1986) 1.87

Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1984) 1.81

In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect (1999) 1.57

Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax (2003) 1.52

Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother (2003) 1.52

Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol (2002) 1.41

Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. J Antimicrob Chemother (2001) 1.24

Population structure and antibiotic resistance of Acinetobacter DNA group 2 and 13TU isolates from hospitals in the UK. J Med Microbiol (2002) 1.17

Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia. Mol Microbiol (2000) 1.12

Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis (2002) 1.11

In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother (2003) 0.93

Clinical features of pandrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Taiwan. J Formos Med Assoc (2003) 0.88

[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii]. Rev Esp Quimioter (2001) 0.85

Selective cleavage of a peptide antibiotic, colistin by colistinase. J Antibiot (Tokyo) (1980) 0.82

[Inhaled colistin in cystic fibrosis]. Schweiz Med Wochenschr (2000) 0.80

Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis (2005) 6.60

Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis (2010) 4.27

High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest (2005) 3.58

Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care (2006) 3.35

The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol (2006) 3.27

Real-time ultrasound-guided catheterisation of the internal jugular vein: a prospective comparison with the landmark technique in critical care patients. Crit Care (2006) 3.17

The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med (2015) 2.75

Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents (2007) 2.58

Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother (2005) 2.47

Bullous erysipelas: clinical presentation, staphylococcal involvement and methicillin resistance. Dermatology (2006) 2.18

Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care (2006) 2.07

β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis (2011) 2.03

Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother (2007) 1.89

Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis (2005) 1.89

Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents (2009) 1.88

The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother (2006) 1.80

Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis (2005) 1.74

Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol (2005) 1.69

Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med (2008) 1.69

Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol (2005) 1.60

Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care (2005) 1.58

Pulmonary mucormycosis. Semin Respir Crit Care Med (2011) 1.58

Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther (2008) 1.56

Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc (2008) 1.56

Impact of initial discordant treatment with beta-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review. Mayo Clin Proc (2006) 1.49

Epstein Barr virus hepatitis. Eur J Intern Med (2010) 1.47

A bibliometric analysis by geographic area of published research in several biomedical fields, 1995-2003. CMAJ (2006) 1.46

Microbiologically documented nosocomial infections after coronary artery bypass surgery without cardiopulmonary bypass. J Thorac Cardiovasc Surg (2006) 1.45

Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis (2009) 1.44

A prospective study of services utilization of a hospital-based employee health clinic. Med Sci Monit (2006) 1.42

Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis (2005) 1.40

A bibliometric analysis of research productivity in Parasitology by different world regions during a 9-year period (1995-2003). BMC Infect Dis (2006) 1.40

Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother (2006) 1.39

Cefuroxime as antibiotic prophylaxis in coronary artery bypass grafting surgery. Interact Cardiovasc Thorac Surg (2007) 1.39

From conference abstract to full paper: differences between data presented in conferences and journals. FASEB J (2005) 1.39

Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother (2009) 1.38

Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents (2008) 1.36

Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents (2005) 1.36

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents (2009) 1.35

Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther (2007) 1.34

Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand J Infect Dis (2005) 1.33

Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents (2012) 1.32

Eighteen years of research on AIDS: contribution of and collaborations between different world regions. AIDS Res Hum Retroviruses (2006) 1.31

Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer (2013) 1.31

Patterns and early evolution of organ failure in the intensive care unit and their relation to outcome. Crit Care (2012) 1.26

A bibliometric analysis of global trends of research productivity in tropical medicine. Acta Trop (2006) 1.24

Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine. J Infect (2002) 1.23

Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials. Am J Med Sci (2007) 1.22

Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc (2005) 1.20

Peritoneal dialysis-associated peritonitis: clinical features and predictors of outcome. Int J Infect Dis (2009) 1.20

Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents (2010) 1.18

Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents (2006) 1.16

The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res (2006) 1.14

Outcomes after medical and surgical treatment of diverticulitis: a systematic review of the available evidence. J Gastroenterol Hepatol (2007) 1.12

Invasive non-typhoidal salmonellosis in immunocompetent infants and children. Int J Infect Dis (2006) 1.10

Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime. J Infect (2007) 1.09

Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies. Antimicrob Agents Chemother (2006) 1.06

Endocrine and metabolic manifestations of invasive fungal infections and systemic antifungal treatment. Mayo Clin Proc (2008) 1.05

Home blood pressure monitoring in the diagnosis and treatment of hypertension: a systematic review. Am J Hypertens (2010) 1.04

Outcome of critically ill oldest-old patients (aged 90 and older) admitted to the intensive care unit. J Am Geriatr Soc (2006) 1.04

Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world. Antimicrob Agents Chemother (2006) 1.03

Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit Care Med (2006) 1.03

Estimates of global research productivity in virology. J Med Virol (2005) 1.03

Arab science in the golden age (750-1258 C.E.) and today. FASEB J (2006) 1.02

Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis (2008) 1.01

Multiple myeloma involving the central nervous system: a report of two cases with unusual manifestations. Leuk Lymphoma (2005) 1.00

Mortality and morbidity of HIV infected patients receiving HAART: a cohort study. Curr HIV Res (2008) 1.00

Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. Am J Infect Control (2007) 1.00

Changing antibiotic susceptibilities of community-acquired uropathogens in Greece, 2005-2010. J Microbiol Immunol Infect (2012) 0.99

Corticosteroids block autophagy protein recruitment in Aspergillus fumigatus phagosomes via targeting dectin-1/Syk kinase signaling. J Immunol (2013) 0.97

Fatal Nocardia farcinica bacteremia in a patient with lung cancer. Diagn Microbiol Infect Dis (2004) 0.96

Bacteremic community-acquired pneumonia due to Pasteurella multocida. Int J Infect Dis (2008) 0.96

Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series. Respir Med (2008) 0.95

Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study. Oncology (2006) 0.95

Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolates. Int J Antimicrob Agents (2007) 0.94

Comparison of utility of blood cultures from intravascular catheters and peripheral veins: a systematic review and decision analysis. J Med Microbiol (2008) 0.93

Ochrobactrum anthropi bacteremia in pediatric oncology patients. Pediatr Infect Dis J (2002) 0.92

Worldwide research productivity in critical care medicine. Crit Care (2005) 0.92

Incidence, clinical, microbiological features and outcome of bloodstream infections in patients undergoing hemodialysis. Int J Med Sci (2013) 0.91

Venetian rule and control of plague epidemics on the Ionian Islands during 17th and 18th centuries. Emerg Infect Dis (2009) 0.91

Infections of respiratory or abdominal origin in ICU patients: what are the differences? Crit Care (2010) 0.91

Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials. J Antimicrob Chemother (2007) 0.90

Clinical significance and antibiotic susceptibilities of nontuberculous mycobacteria from patients in Crete, Greece. Future Microbiol (2011) 0.90

Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis (2005) 0.90